Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Daiichi Sankyo: Enhertu significantly improves progression-free survival in HER2‑mutated NSCLC
In the phase‑3 DESTINY‑Lung04 trial, Enhertu as first‑line therapy for HER2‑mutated non‑small‑cell lung cancer showed a significantly longer progression‑free survival (median 14.3 vs. 8.3 months) and reduced the risk of progression or death by 37% (HR 0.63) versus pembrolizumab plus chemotherapy. The objective response rate was 70% versus 44.5%, with median duration of response 13.4 versus 9.7 months. The safety profile was consistent with prior knowledge; treatment‑related grade‑3 events occurred in 34.1%, and interstitial lung disease/pneumonitis in 20.8% with four grade‑5 cases. » Mere på de.investing.com
Daiichi Sankyo rises after partner Merck reports positive study result
Daiichi Sankyo’s shares gained 6.1% after Merck, in partnership with Moderna, reported positive results for a personalized skin cancer vaccine in a late-stage trial. Daiichi was not directly involved in that specific study but benefited from improved sentiment toward Merck, Moderna and their global partners. The price increase helped lift the Nikkei 225 and highlights Daiichi’s sensitivity as a leading Japanese developer of cancer therapies to industry news. » Mere på de.investing.com
Daiichi Sankyo: CHMP recommends approval of Enhertu for HER2-positive solid tumors
The CHMP of the EMA has recommended approval of Enhertu (trastuzumab deruxtecan) for adult patients with inoperable or metastatic HER2-positive solid tumors. The recommendation is based on three phase II studies showing confirmed objective response rates of about 47–52% and a median duration of response of 5.5 to 14.2 months. The safety profile was consistent with earlier trials; neutropenia, anemia and pneumonic events were observed. The final decision now rests with the European Commission. » Mere på de.investing.com
Daiichi Sankyo exceeds EPS forecasts significantly thanks to oncology growth
Daiichi Sankyo reported Q4 earnings per share of 70.02 JPY versus a forecast of 55.37 JPY, a positive surprise of 26.46%. Quarterly revenue was 589.71 billion JPY, slightly above expectations; the stock rose 2.04% after the results. Strong growth in the oncology segment, notably driven by ENHERTU, propelled the performance; fiscal-year revenue increased by 12.6%, while operating profit declined due to special items. For 2026 the company expects further oncology growth and additional milestone payments but remains exposed to risks such as supply-chain disruptions and higher costs. » Mere på de.investing.com
Daiichi Sankyo expands 'One DS Culture' to a distributed global model to sustain oncology momentum
Daiichi Sankyo is consolidating its global transformation around a "One DS Culture," shifting to a distributed global structure that empowers regional autonomy while maintaining a unified corporate identity. The company emphasizes in-house R&D and long-term innovation in antibody‑drug conjugates as the core growth strategy, promoting merit-based, science-driven decision making. Leadership development, clear decision criteria and encouraging proactive "spillover" behaviors are being used to preserve agility and drive continued global expansion in oncology. » Mere på forbes.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 3,32 mia. | 15,15 % |
| Bruttofortjeneste | 2,64 mia. | 32,95 % |
| Nettoresultat | 473,02 mio. | 81,31 % |
| EBITDA | 731,25 mio. | 64,75 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 29,75 mia. € |
Antal aktier | 1,82 mia. |
Højeste/laveste i 52 uger | 22,26 € - 13,60 € |
Udbytteafkast | 2,62 % |
Udbytte TTM | 0,43 € |
Næste udbytte | 0,28 € |
Beta | 0,80 |
P/E (PE Ratio) | 18,74 |
PEG (PEG Ratio) | 7,90 |
K/I (PB Ratio) | 3,03 |
P/S (PS Ratio) | 2,26 |
Virksomhedsprofil
Daiichi Sankyo Company, Limited forsker i, udvikler, fremstiller, importerer, markedsfører og sælger farmaceutiske produkter over hele verden. Virksomheden tilbyder trastuzumab deruxtecan, et antikræftmiddel og et anti-HER2 antistof-lægemiddelkonjugat; mirogabalin til smertebehandling; teneligliptin/canagliflozin til behandling af type 2-diabetes mellitus; lacosamid, et antiepileptisk middel; prasugrel, et antitrombocytmiddel; denosumab til osteoporose og knoglelidelser; teneligliptin til behandling af type 2-diabetes mellitus; edoxaban, et antikoagulerende middel; esomeprazol til behandling af sår; memantin til behandling af Alzheimers sygdom; og laninamivir til behandling af influenza. Virksomheden leverer også olmesartan, et blodtrykssænkende middel; levofloxacin, et antibakterielt middel; pravastatin til behandling af hyperkolesterolæmi; og loxoprofen, et antiinflammatorisk smertestillende middel. Derudover tilbyder virksomheden colesevelam til behandling af hyperkolesterolæmi og type 2-diabetes mellitus; samt jernkarboxymaltose og jernsucrose-injektioner til behandling af anæmi. Desuden leverer den Lulu, et kombineret middel mod forkølelse; Loxonin S, et febernedsættende og smertestillende/antiinflammatorisk middel; Transino til forbedring af melasma og behandling af pletter og fregner; Minon, et hudplejeprodukt; samt Breath Labo og Clean Dental mundplejeprodukter; desuden Silodosin til dysuri; Gefitinib til maligne tumorer; Bicalutamid til prostatakræft; og Tamoxifen, et middel mod brystkræft. Endvidere tilbyder virksomheden adsorberede cellekulturbaserede influenzavacciner, influenza HA-vacciner, kombineret mæslinger-røde hunde-vaccine og fåresygevacciner. Den leverer også lægemidler og medicin til dyr, kosmetik, medicinsk udstyr, fødevarer, drikkevand, aktive farmaceutiske ingredienser og mellemprodukter. Virksomheden samarbejder med Guardant Health om at udvikle Guardant360 CDx som et companion diagnostic til Enhertu ved fremskreden metastatisk ikke-småcellet lungecancer. Virksomheden blev grundlagt i 1899 og har hovedsæde i Tokyo, Japan.
| Navn | Daiichi Sankyo |
| CEO | Hiroyuki Okuzawa |
| Hjemsted | Tokyo,
ty Japan |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 04.01.2000 |
| Medarbejdere | 20.171 |
Tickersymboler
| Børs | Symbol |
|---|---|
Pnk | DSKYF |
Japan Exchange Group | 4568.T |
Frankfurt | D4S.F |
Düsseldorf | D4S.DU |
München | D4S.MU |